Oruka Therapeutics (ORKA) Competitors $25.38 -1.09 (-4.12%) (As of 09/18/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsTrends ORKA vs. VNRX, ABIO, ICCC, OCX, TRIB, AWH, CDIO, BMRA, MYMD, and VRAXShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include VolitionRx (VNRX), ARCA biopharma (ABIO), ImmuCell (ICCC), OncoCyte (OCX), Trinity Biotech (TRIB), Aspira Women's Health (AWH), Cardio Diagnostics (CDIO), Biomerica (BMRA), MyMD Pharmaceuticals (MYMD), and Virax Biolabs Group (VRAX). These companies are all part of the "diagnostic substances" industry. Oruka Therapeutics vs. VolitionRx ARCA biopharma ImmuCell OncoCyte Trinity Biotech Aspira Women's Health Cardio Diagnostics Biomerica MyMD Pharmaceuticals Virax Biolabs Group VolitionRx (NYSE:VNRX) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends. Do analysts recommend VNRX or ORKA? VolitionRx currently has a consensus target price of $2.50, indicating a potential upside of 287.60%. Oruka Therapeutics has a consensus target price of $41.25, indicating a potential upside of 62.53%. Given VolitionRx's higher possible upside, equities research analysts plainly believe VolitionRx is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Which has preferable valuation & earnings, VNRX or ORKA? Oruka Therapeutics has lower revenue, but higher earnings than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$770K73.46-$35.32M-$0.46-1.34Oruka TherapeuticsN/AN/A-$5.34MN/AN/A Does the media refer more to VNRX or ORKA? In the previous week, Oruka Therapeutics had 16 more articles in the media than VolitionRx. MarketBeat recorded 18 mentions for Oruka Therapeutics and 2 mentions for VolitionRx. Oruka Therapeutics' average media sentiment score of 0.44 beat VolitionRx's score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VolitionRx 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, VNRX or ORKA? VolitionRx has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Does the MarketBeat Community favor VNRX or ORKA? Oruka Therapeutics received 3 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 100.00% of users gave Oruka Therapeutics an outperform vote while only 13.33% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformVolitionRxOutperform Votes413.33%Underperform Votes2686.67% Oruka TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Is VNRX or ORKA more profitable? Oruka Therapeutics has a net margin of 0.00% compared to VolitionRx's net margin of -3,318.42%. VolitionRx's return on equity of 0.00% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-3,318.42% N/A -165.21% Oruka Therapeutics N/A -20.18%-19.51% Do institutionals & insiders have more ownership in VNRX or ORKA? 8.1% of VolitionRx shares are held by institutional investors. 12.8% of VolitionRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryOruka Therapeutics beats VolitionRx on 10 of the 16 factors compared between the two stocks. Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.71M$2.99B$5.67B$8.24BDividend YieldN/A0.71%4.36%4.08%P/E RatioN/A162.79144.2618.58Price / SalesN/A40.741,618.0472.36Price / CashN/A16.9937.2331.90Price / Book0.733.524.814.52Net Income-$5.34M$28.57M$115.07M$223.87M7 Day Performance-14.31%-2.16%3.80%4.99%1 Month PerformanceN/A-7.29%8.94%8.34%1 Year PerformanceN/A-14.30%28.77%11.85% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNRXVolitionRx1.8434 of 5 stars1.84 / 5 stars$0.68-2.9%$2.50+267.9%-47.1%$56.36M$976,516.00-1.4880Analyst ForecastNews CoverageGap DownABIOARCA biopharma0.592 of 5 stars0.59 / 5 stars$2.40-4.0%N/A-99.2%$34.82MN/A-5.716Gap DownICCCImmuCell0.1692 of 5 stars0.17 / 5 stars$3.63flatN/A-32.1%$28.42M$17.47M-7.1270Gap DownOCXOncoCyte2.2228 of 5 stars2.22 / 5 stars$3.08-0.6%$4.06+31.9%-12.3%$25.48M$1.02M0.00120TRIBTrinity Biotech1.0982 of 5 stars1.10 / 5 stars$1.60-1.8%N/A-61.3%$12.20M$58.65M-0.57480Gap DownAWHAspira Women's Health2.8057 of 5 stars2.81 / 5 stars$0.85+1.3%$4.40+417.0%-85.7%$10.60M$8.92M-0.59110Analyst UpgradeShort Interest ↓Gap UpCDIOCardio Diagnostics2.6533 of 5 stars2.65 / 5 stars$0.30+2.5%$2.00+569.8%-39.6%$6.77M$39,138.000.001News CoverageBMRABiomerica0.5635 of 5 stars0.56 / 5 stars$0.30-0.7%N/A-72.1%$5.10M$5.41M-0.8260MYMDMyMD Pharmaceuticals0 of 5 stars0.00 / 5 stars$1.82+23.4%N/A-92.6%$4.31MN/A0.009Gap UpVRAXVirax Biolabs Group0.4676 of 5 stars0.47 / 5 stars$2.59-1.5%N/A-25.3%$4.03M$156,419.000.005Gap Down Related Companies and Tools Related Companies: VNRX Competitors ABIO Competitors ICCC Competitors OCX Competitors TRIB Competitors AWH Competitors CDIO Competitors BMRA Competitors MYMD Competitors VRAX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORKA) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
